References
- Cavenagh J D, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18–26
- Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831
- Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
- Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Hematol 2004; 79: 283–288
- Rajkumar S V, Dispenzieri A, Fonseca R, Lacy M Q, Geyer S, Lust J A, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276
- Koc S, Leisenring W, Flowers M E, Anasetti C, Deeg H J, Nash R A, et al. Thalidomide for treatment of patients with chronic graft-vs.-host disease. Blood 2000; 96: 3995–3996
- Parker P M, Chao N, Nademanee A, O'Donnell M R, Schmidt G M, Snyder D S, et al. Thalidomide as a salvage therapy for chronic graft-vs.-host disease. Blood 1995; 86: 3604–3609
- Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067